The Jharkhand market grew the highest at 36.4 per cent followed by Vidarbha at 32.5 per cent
The Indian Pharma Market (IPM) clocked Rs 7738 crores in September 2014. It has seen a growth of 18.8 per cent in the same month. Amongst the top 10, Cipla grew by 38.4 per cent followed by Mankind at 30.9 per cent and Pfizer at 23.9 per cent. The company became the number one company in September.
23 corporates have crossed the growth of IPM in September amongst top 50. Amongst the top 50 corporates, Akumentis has the highest growth of 92.5 per cent followed by Apex at 62.2 per cent and Bharat Serums at 49.9 per cent. 12 corporates showed growths more than 30 per cent amongst the top 50.
|
With Bonus Units at Full Value
|
||||||||
|
Val in Crs
|
Rank
|
MAT Sep -14
|
Sep-14
|
|||||
|
CORPORATE
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
| IPM |
80565
|
100.00
|
9.1
|
7738
|
100.00
|
18.8
|
||
| Abbott + Abbott HC + Novo |
1
|
1
|
5030
|
6.24
|
5.8
|
467
|
6.03
|
16.7
|
| Sun Pharma |
2
|
3
|
4343
|
5.39
|
15.0
|
378
|
4.89
|
8.9
|
| Cipla |
3
|
2
|
4038
|
5.01
|
10.3
|
427
|
5.51
|
38.4
|
| Zydus + Biochem |
4
|
4
|
3480
|
4.32
|
8.0
|
312
|
4.03
|
12.0
|
| Ranbaxy |
5
|
7
|
2908
|
3.61
|
4.9
|
273
|
3.53
|
15.8
|
| Mankind |
6
|
5
|
2899
|
3.60
|
10.2
|
305
|
3.95
|
30.9
|
| Alkem + Cachet + Indchemie |
7
|
6
|
2887
|
3.58
|
13.8
|
290
|
3.75
|
19.1
|
| Glaxo |
8
|
8
|
2729
|
3.39
|
-11.1
|
264
|
3.41
|
14.9
|
| Lupin |
9
|
9
|
2710
|
3.36
|
12.8
|
259
|
3.35
|
19.7
|
| Pfizer |
10
|
12
|
2348
|
2.91
|
6.3
|
229
|
2.96
|
23.9
|
| Macleods |
11
|
10
|
2279
|
2.83
|
21.4
|
244
|
3.15
|
44.2
|
| Emcure + Zuventus |
12
|
14
|
2193
|
2.72
|
11.1
|
191
|
2.47
|
4.9
|
| Intas |
13
|
13
|
2098
|
2.60
|
15.3
|
195
|
2.51
|
18.8
|
| Aristo |
14
|
11
|
2023
|
2.51
|
19.9
|
230
|
2.98
|
39.7
|
| Sanofi India |
15
|
16
|
1984
|
2.46
|
-0.5
|
180
|
2.32
|
13.2
|
| Torrent |
16
|
18
|
1779
|
2.21
|
5.4
|
167
|
2.15
|
18.4
|
| Glenmark |
17
|
15
|
1754
|
2.18
|
16.6
|
185
|
2.39
|
27.0
|
| Dr. Reddys |
18
|
17
|
1719
|
2.13
|
9.4
|
167
|
2.15
|
17.5
|
| Micro + Bal |
19
|
20
|
1616
|
2.01
|
12.0
|
143
|
1.85
|
4.6
|
| Ipca |
20
|
19
|
1470
|
1.82
|
24.7
|
152
|
1.96
|
22.1
|
| USV |
21
|
21
|
1466
|
1.82
|
10.0
|
128
|
1.66
|
7.6
|
| Novartis |
22
|
23
|
1145
|
1.42
|
-1.0
|
105
|
1.36
|
13.4
|
| Alembic |
23
|
22
|
1103
|
1.37
|
12.8
|
117
|
1.51
|
30.6
|
| Wockhardt |
24
|
25
|
993
|
1.23
|
6.1
|
84
|
1.09
|
7.6
|
Amongst the 11-20 ranked corporates, Macleods has the highest growth of 44.2 per cent followed by Aristo at 39.7 per cent and Glenmark at 27 per cent. Amongst the 51-60 ranked corporates, Eli Lilly grows at 34.9 per cent followed by Allergan at 31.3 per cent and Pharmed at 26 per cent.
Amongst the 61-75 ranked corporates, Boehringer grew by 88.8 per cent followed by Corona at 27.8 per cent and British Biological at 27.4 per cent.
Indian companies have grown at 19.8 per cent versus 16 per cent for MNCs in September 2014. Amongst the top 50 in MNCs, Pfizer grew by 23.9 per cent followed by Janssen at 18.8 per cent and Abbott at 16.7 per cent.
Under the non-NLEM category Indian companies grew at 21.7 per cent whereas MNCs grew at 17.8 per cent.
The DPCO 2013 containing molecules market grew at 10.8 per cent whereas the non-DPCO market grew by 20.7 per cent resulting in an overall growth of 18.8 per cent for September 2014. NLEM and non-NLEM category showed positive unit growth at 6.6 per cent and 12.1 per cent respectively. The DPCO 2013 portfolio for Pfizer grew at 6.2 per cent, GSK 12.9 per cent and Ranbaxy 19.7 per cent.
From the therapy perspective, nine therapies have outgrown the IPM growth and 18 therapies have double digit growths. The respiratory market grew at 28.6 per cent, gastrointestinal market grew at 19.4 per cent, pain and analgesics market grew at 17.7 per cent whereas the anti-infectives grew at 23.3 per cent. The anti-diabetic market grows at 24.6 per cent and the cardiac at 13.1 per cent in chronic business. The derma market grew by 19.1 per cent and the urology market at 29.9 per cent.
From the regional perspective, 13 regions have outgrown the IPM growth. The Jharkhand market grew the highest at 36.4 per cent followed by Vidarbha market at 32.5 per cent and Madhya Pradesh at 32.3 per cent. No region had negative growth in September 2014. Amoxycillin + Clavulanic acid market grows at 34 per cent whereas Glimepiride + Metformin grows at 13.3 per cent and is at number two.
|
Val in Crs
|
MAT Sep 14
|
Month Sep-14
|
||
|
Super Group
|
Val in Crs
|
GR%
|
Val in Crs
|
GR%
|
| IPM |
80565
|
9.1
|
7738
|
18.8
|
| ANTI-INFECTIVES |
13075
|
3.8
|
1390
|
23.3
|
| CARDIAC |
9961
|
9.3
|
891
|
13.1
|
| GASTRO INTESTINAL |
9252
|
10.7
|
874
|
19.4
|
| VITAMINS / MINERALS / NUTRIENTS |
7183
|
9.6
|
691
|
18.7
|
| RESPIRATORY |
6263
|
11.1
|
622
|
28.6
|
| ANTI DIABETIC |
5922
|
19.5
|
561
|
24.6
|
| PAIN / ANALGESICS |
5795
|
8.3
|
564
|
17.7
|
| NEURO / CNS |
5025
|
7.7
|
448
|
10.3
|
| DERMA |
4550
|
15.4
|
436
|
19.1
|
| GYNAECOLOGICAL |
4143
|
3.7
|
371
|
11.0
|
| OPHTHAL / OTOLOGICALS |
1459
|
11.3
|
141
|
22.2
|
| HORMONES |
1332
|
3.9
|
123
|
11.4
|
| ANTI-NEOPLASTICS |
1306
|
28.4
|
114
|
29.1
|
| VACCINES |
1149
|
-8.5
|
104
|
9.6
|
| BLOOD RELATED |
986
|
3.7
|
86
|
3.9
|
| OTHERS |
906
|
6.0
|
85
|
16.9
|
| UROLOGY |
819
|
17.3
|
83
|
29.9
|
| ANTI MALARIALS |
620
|
7.0
|
82
|
15.0
|
| SEX STIMULANTS / REJUVENATORS |
455
|
3.6
|
38
|
10.4
|
| STOMATOLOGICALS |
364
|
12.3
|
35
|
20.2
|
The markets of Paracetamol grew at 28.1 per cent, Atorvastatin 14.7 per cent, Azithromycin at 39.7 per cent, Probiotic Microbes at 40.3 per cent, Cefixime 21 per cent, Pantoprazole 21 per cent, Montelukast + Levocetrizine at 36.6 per cent, Glimepiride + Metformin + Pioglitazone at 18.6 per cent, Vitamin-D at 39.6 per cent, Hydroquinone + Mometasone + Tretinoin at 13.3 per cent, Voglibose + Metformin + Glimepiride at 39.1 per cent, Telmisartan + Metoprolol at 41.3 per cent.
Mixtard continues to lead the pack with Rs 35.2 crores in September with a growth of 38.8 per cent. Augmentin grows at 52.1 per cent, followed by Monocef at 45.7 per cent and Lantus at 42.2 per cent amongst the top 10 brands.
Amongst the brands who have gained ranks include Augmentin and Glycomet-GP (+1), Lantus (+9), Galvus Met (+6), Taxim-O (+4), Moxikind CV (+7), Spasmoproxyvon Plus (+37), Zincovit (+17), Thyronorm (+27), Novomix (+12),Panderm Plus (+77), Jalra M (+29), Sinarest (+5), Shelcal (+16) amongst Top 100 brands over September 13.
On MAT basis, Bifilac has entered into the Top 300 brands. Amongst the top brands in the IPM, Spasmoproxyvon Plus (67 per cent), Augmentin (52.1 per cent), Monocef (45.7 per cent), Taxim O (33 per cent), Aciloc (26.2 per cent),Dexorange (22.7 per cent), Liv-52(19.5 per cent), Glycomet-GP (14.9 per cent) grew fastest amongst the top 30 brands over September 2013
A total 283 brands were launched in September 2014. Felbinac is a new subgroup launched in the same month.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net